Clinical Trials Logo

Filter by:
NCT ID: NCT03291457 Completed - Clinical trials for Rheumatoid Arthritis

A Study to Evaluate the Use of Glucocorticoids in Combination With Tocilizumab in Daily Clinical Practice

COGNOS
Start date: March 30, 2017
Phase:
Study type: Observational

This prospective, multicenter, observational study will evaluate the use of concomitant glucocorticoid therapy in adults with rheumatoid arthritis (RA) being treated with tocilizumab in daily clinical practice. Participants will be observed for up to 52 weeks after starting treatment with tocilizumab. All visits and assessments will be performed as per routine clinical practice, with no study-specific visits or interventions.

NCT ID: NCT03291314 Completed - Clinical trials for Recurrent Glioblastoma (WHO-Grade IV Glioma)

Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma

GliAvAx
Start date: May 3, 2017
Phase: Phase 2
Study type: Interventional

Phase II clinical trial on the combination of avelumab and axitinib for the treatment of patients with recurrent glioblastoma (histologically confirmed WHO grade IV glioma), at documented recurrence/progression following prior treatment with surgery, radiation therapy and temozolomide.

NCT ID: NCT03291184 Completed - Clinical trials for Postoperative Residual Curarization

Postoperative Residual Paralysis After Cardiac Surgery

Start date: September 4, 2017
Phase: N/A
Study type: Interventional

The main objective of this study is to describe the incidence of postoperative residual paralysis (mean train-of-four <90%) when weaning from the ventilator in patients admitted to the Intensive Care Unit (ICU) after elective cardiac surgery. Train-of-four monitoring is a widely used term for the peripheral nerve stimulation used in neuromuscular blockade monitoring. When the patient is ready for weaning from the ventilator, an ICU doctor will perform a measurement of the train-of-four at the thumb with a neuromuscular transmission monitor. Every value below 90% will be considered as residual paralysis and treated appropriately by means of a reversal agent.

NCT ID: NCT03291171 Completed - Chronic Disease Clinical Trials

Identifying the Effect and Working Mechanisms of MyPlan 2.0 in Adults With Type 2 Diabetes

Start date: October 15, 2017
Phase: N/A
Study type: Interventional

The aim of this study is to investigate whether and how 'MyPlan 2.0' helps adults with type 2 diabetes to be more physically active or less sedentary. Two groups will be created, an intervention group and a waiting-list control group.

NCT ID: NCT03290781 Completed - Ulcerative Colitis Clinical Trials

An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis

FIGARO UC 303
Start date: April 4, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of ontamalimab as maintenance therapy treatment of remission, based on composite score of patient-reported symptoms and centrally read endoscopy, in participants with moderate to severe ulcerative colitis (UC).

NCT ID: NCT03289273 Completed - Liver Neoplasms Clinical Trials

Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)

Start date: September 13, 2017
Phase:
Study type: Observational

Observational study to evaluate, under real-world practice conditions, the safety and effectiveness of regorafenib in patients diagnosed with unresectable hepatocellular carcinoma (uHCC)

NCT ID: NCT03288675 Completed - Clinical trials for Depressive Disorder, Major

Stepped Care aiTBS 2 Depression Study (Ghent)

aiTBS2-Ghent
Start date: October 5, 2017
Phase: N/A
Study type: Interventional

Antidepressant-free unipolar melancholic depressed patients (at least stage 2 treatment-resistant) will be selected by a certified psychiatrist, who will administer (semi-)structured clinical interviews. Because concomitant antidepressant treatment can confound outcome results, all patients will go through a medication washout before entering the study and they will be free from any antidepressant, neuroleptic and mood stabilizer for at least two weeks before entering the treatment protocol. Only habitual benzodiazepine agents will be allowed. STEP 1: Patients will be treated with in total 20 accelerated intermittent Theta Burst Stimulation (aiTBS) sessions (3000 pulses/session) over the left dorsolateral prefrontal cortex, which will be spread over 4 days. On each stimulation day, a given patient will receive 5 sessions with a between-session delay of 15 minutes. Patients will be randomized to receive either the real aiTBS or sham treatment (first week). However, the sham group will receive real aiTBS treatment with 10 days' time interval. The investigators expect that real aiTBS treatment and not sham will result in a significant and clinical meaningful response. STEP 2: To optimize treatment and reduce relapse following the iTBS treatment, in a stepped care approach, all patients then continue with cognitive control training (CCT) ten days later. This CCT consists of 20 sessions, spread over 4 weeks. Patients will be randomized to receive either real CCT or a control training. During this follow-up treatment, all patients will be prescribed antidepressant medication (SSRI) again. As iTBS treatment effects are known to decline over time, the investigators expect that combining aiTBS with a follow-up CCT therapy will stabilize the clinical effects over time compared to receiving the iTBS treatment alone. For baseline comparisons, patients will be closely matched for gender and age with never-depressed, medication-free healthy volunteers. No volunteer will undergo treatment.

NCT ID: NCT03286088 Completed - Clinical trials for Mitral Valve Regurgitation of Any Grade

Mitral Valve Regurgitation Quantification From 3D Color Doppler Ultrasound - Standard of Care Data Collection

Start date: August 22, 2017
Phase: N/A
Study type: Interventional

The study primarily aims to collect standard of care clinical data in a wide spectrum of simple to complex mitral valve regurgitation (MVR) cases to validate a post-processing stand-alone software prototype (QFlow), developed by Philips Research Paris (Medisys). Investigator does not intervene in the care of the patient, but simply collects standard of care images and measurements that are needed for the validation of the investigational software.

NCT ID: NCT03285009 Completed - Injuries Clinical Trials

Movement Patterns in Young Volleyball Athletes

Start date: September 25, 2017
Phase: N/A
Study type: Interventional

This project is a consequence of the research chair project studying the same phenomenon in adult volleyball players. The project will make use of and be part of the routine medical screening that is taken by the young players of the first degree of the Leuven Volleyball School, Belgium. All young players must undergo a routine medical investigation and movement screening. This is obliged by the law. The current project will use these data. Outcome parameters will be used to advice the trainer staff of the school to adjust their training interventions. This is normal routine too as the involved medical department has been advising the school for many years. Players will be followed up for 6 weeks. After those 6 weeks, the movement screening will be repeated to evaluate the change in the different outcome parameters. This last screening is not part of a normal routine as players normally are investigated more in a subjective way. The medical team and school want to change that routine. Data will be used to further improve training modalities and sports performance and reduce injury risk in these young athletes.

NCT ID: NCT03284853 Completed - Ocular Hypertension Clinical Trials

Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension

Start date: September 5, 2017
Phase: Phase 3
Study type: Interventional

The study is intended to test the effectiveness and safety of Netarsudil / Latanoprost 0.02% / 0.005% Ophthalmic Solution, relative to GANFORT® for lowering of intraocular pressure (IOP) in patients with elevated intraocular pressure